ASSESSMENT OF POTENTIAL COCAINE TREATMENT MEDICATIONS

这代表着NIDA合同N01DA-2-9306的竞争性续签， 题为《#年潜在可卡因治疗药物的评估》 猴子。研究和开发的主要目标 这里描述的项目是筛选潜在的药物疗法 可卡因滥用评价化合物在药物辨别和自我评价中的应用 非人灵长类动物的管理范例。这些测试已经被 被NIDA的药物开发部(MDD)选中，因为他们 被认为代表了可以预测临床的模型系统 可卡因依赖药物治疗的疗效。由此产生的结果 NIDA的MDD将利用该项目做出有关以下方面的决策 选择要进一步开发的化合物(即毒物学 评估和初步临床评估)作为治疗 可卡因依赖。 简而言之，本合同的目的是确定 用以下范式测试化合物：(1)药物辨别试验 在非人类灵长类动物中单独测试或与可卡因联合测试 (即，测试化合物的主观特征的临床前评估)， 和(2)非人类灵长类动物的自我给药试验 阻止可卡因自我管理或直接自我管理的能力 给予(即，增强属性的临床前评估 和滥用的可能性)。本合同的预期最终结果 是详细说明研究结果的书面报告。

This represents a competitive renewal of NIDA contract N01DA-2-9306, entitled "Assessment of Potential Cocaine Treatment Medications in Monkeys". The primary objective of the research and development project described herein is to screen potential pharmacotherapies for cocaine abuse by evaluating compounds in drug discrimination and self- administration paradigms in nonhuman primates. These tests have been selected by NIDA's medications Development Division (MDD) because they are believed to represent model systems that are predictive of clinical efficacy of pharmacotherapies for cocaine dependence. Results from this project will be utilized by NIDA's MDD to make decisions regarding selection of compounds for further development (i.e., toxicological evaluation and initial clinical evaluation) as pharmacotherapies for cocaine dependence. In brief, the objectives of this contract are to determine the effects of test compounds in the following paradigms: (1) drug discrimination test in nonhuman primates when tested alone or in combination with cocaine (i.e., a preclinical evaluation of the test compound's subjective profile), and (2) self-administration test in nonhuman primates when tested for ability to block cocaine self-administration or to be directly self- administered (i.e., a preclinical evaluation of the reinforcing properties and potential for abuse). The anticipated end results of this contract are written reports detailing study findings.